MedImmune Loss Widens on Charges, R D  NEW YORK (Reuters) - MedImmune Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=MEDI.O target=/stocks/quickinfo/fullquote"&gt;MEDI.O&lt;/A&gt;, maker of the  nasal spray flu vaccine FluMist, on Thursday said its  third-quarter loss widened on higher costs and one-time  charges.